Kate J. Newberry

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak et al. · The Lancet Oncology · 2012 · 296 citations

Phase 1/2, Lymphoid Neoplasia, Hematological Malignancy +8

Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms

Masoud Vedadi, J. Lew, J.D. Artz et al. · Molecular and Biochemical Parasitology · 2006 · 235 citations

Biology, Related Apicomplexan Organisms, Genome-scale Protein Expression +10

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Kate J. Newberry, Keyur P. Patel, Lucia Masárová et al. · Blood · 2017 · 210 citations · Full text

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

M Wang, Nathan Fowler, Nicolaus A. Wagner‐Bartak et al. · Leukemia · 2013 · 203 citations

Lymphoid Neoplasia, Medicine, Malignant Blood Disorder +6